Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Figure out How to Remain Informed about the Most recent Open Record Extra Offers- 'Zootopia 2' movie reviews: A heartwarming, hysterical and earnest 'ode to community'
- The most effective method to Pick the Right Volvo XC40 Trim for Your Way of life
- King Charles III says he is reducing cancer treatment schedule in 2026
- Figure out How to Put resources into Lab Precious stones
- What’s your chronotype? Knowing whether you’re a night owl or an early bird could help you do better on tests and avoid scams
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- Air Force made critical errors during October 7 massacre, investigator says
- Real time features for Films and Programs
